Neurogene (NGNE) Non Operating Investment Income (2020)

Neurogene's (NGNE) quarterly Non Operating Investment Income came in at $7.8 million in Q3 2020.

Neurogene (NGNE) Non Operating Investment Income (2020) Analysis & Trends

Neurogene (NGNE) has 1 years of Non Operating Investment Income data on file, last reported at $7.8 million in Q3 2020.

Quarterly Non Operating Investment Income changed N/A year-over-year to $7.8 million in Q3 2020, while the trailing twelve-month figure through Dec 2021 was $7.8 million (changed N/A YoY) and the FY2020 annual result came in at $7.8 million, changed N/A from the prior year.
Non Operating Investment Income held at $7.8 million in Q3 2020.
In the past five years, Non Operating Investment Income ranged from a high of $7.8 million in Q3 2020 to a low of $7.8 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Neurogene	815.03 Mn	815.03 Mn	-	-

Download Data

Date	Value
Sep 30, 2020	7.83 Mn
Sep 30, 2020	7.83 Mn